Show
Sort by
-
Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients
-
The health-economic implications of the 'Irbesartan in diabetic nephropathy trial' (IDNT) in France and Belgium
-
Discontering van gezondheidswinst in farmaco-economische analyses
-
Dringende geneeskundige hulpverlening
-
Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making
-
Study description and baseline results of the schizophrenia outcomes survey (SOS) observational study in Belgium. Poster presentation at the ISPOR 5th annual European Conference. Rotterdam 3-5/11/2002.
-
Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium.
-
Estimating cost-effectiveness of concerta oros in attention-deficit/hyperactivity disorder (ADHD) - Adapting the Canadian coordinating office for health technology assessment's (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent's perspective. Poster presentation at the ISPOR 5th annual European Conference. Rotterdam 3-5/11/2002.
-
Variation in medical resource utilisation in the management of pulmonary embolism in Belgium.
-
A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.